Why the FDA’s Involvement in AI is a Good Thing

The use of artificial intelligence (AI) in healthcare, particularly radiology, continues to expand, but not without skepticism from clinicians and healthcare leaders. One way for a company to earn trust for its AI solutions is through the rigorous FDA approval process. Qure.ai is proof that it works.

Dr. Samir Shah, Chief Medical Officer at Qure.ai, recently agreed to sit down with Healthcare IT Today to discuss the company’s focus on seeking FDA approval for its AI solutions. To date, they have an industry-leading 18 FDA-cleared AI algorithms. Having that level of approval has helped the company earn trust.

Key Takeaways

1. Regulation Ensures Reliability. Shah believes that rigorous FDA approvals protect against unregulated AI tools, fostering trust in clinical environments.
2. Building Trust in AI is Critical for Further Adoption. AI algorithms cannot be a black box. Clinicians want to know how the algorithm was trained, what datasets it has been exposed to, etc. Transparency is key for AI to be accepted more deeply into clinical practice.
3. AI Designed for Real-World Challenges.ai’s tools tackle critical radiology needs, including detecting lung nodules and fractures, easing the burden on radiologists.

FDA Approval of AI Builds Trust

Dr. Shah explained that FDA approvals are a critical step in ensuring AI tools meet high standards for safety and effectiveness. “Without this regulation, it could be like the wild west,” Shah noted.

For the past several years, the power and potential of AI in clinical practice has enthralled the industry. However, there is hesitation by organizations and clinicians about implementing AI deeply into clinical care – aka using AI to diagnose patients and identify diseases. One reason for that hesitation is that AI algorithms are a black box. Vendors do not make it clear how their algorithms are created, what data they were trained on, and any limitations they have run into while testing it.

Achieving FDA approval is an effective way to address this concern head-on.

“The FDA ask much more rigorous questions and have rigorous standards,” said Dr. Shah. “They know more about AI and how it works. They know about bias, drift and other concepts that were not thought about in the early days of AI.”

By investing the time and resources to meet the FDA’s stringent requirements, Qure.ai is able to show potential buyers that its AI tools are validated. This builds trust which is key to getting their technology adopted by radiologists and healthcare providers.

Qure.ai Continues to Expand AI Usage

Beyond the regulatory triumphs, Qure.ai’s is continuing to push forward to expand the use of its AI solutions. Building on their expertise with plain film, the company is using AI to “distinguish normal from abnormal chest x-rays and looking at fracture detection in fifteen different extremities” according to Dr. Shah.

The company is also working to helping to alleviate the administrative workload on radiologists.

“We are pushing forward with solutions that make a measurable difference,” Dr. Shah emphasized, pointing to their efforts in lung cancer detection as a prime example of the impactful they can have.

By seeking FDA clearance for its AI technology, Qure.ai is paving the way for a more trusted future for AI in healthcare.

Learn more about Qure.ai at https://www.qure.ai/

Listen and subscribe to the Healthcare IT Today Interviews Podcast to hear all the latest insights from experts in healthcare IT.

And for an exclusive look at our top stories, subscribe to our newsletter and YouTube.

Tell us what you think. Contact us here or on Twitter at @hcitoday. And if you’re interested in advertising with us, check out our various advertising packages and request our Media Kit.

The use of artificial intelligence (AI) in healthcare, particularly radiology, continues to expand, but not without skepticism from clinicians and healthcare leaders. One way for a company to earn trust for its AI solutions is through the rigorous FDA approval process. Qure.ai is proof that it works.

Dr. Samir Shah, Chief Medical Officer at Qure.ai, recently agreed to sit down with Healthcare IT Today to discuss the company’s focus on seeking FDA approval for its AI solutions. To date, they have an industry-leading 18 FDA-cleared AI algorithms. Having that level of approval has helped the company earn trust.

Key Takeaways

1. Regulation Ensures Reliability. Shah believes that rigorous FDA approvals protect against unregulated AI tools, fostering trust in clinical environments.
2. Building Trust in AI is Critical for Further Adoption. AI algorithms cannot be a black box. Clinicians want to know how the algorithm was trained, what datasets it has been exposed to, etc. Transparency is key for AI to be accepted more deeply into clinical practice.
3. AI Designed for Real-World Challenges.ai’s tools tackle critical radiology needs, including detecting lung nodules and fractures, easing the burden on radiologists.

FDA Approval of AI Builds Trust

Dr. Shah explained that FDA approvals are a critical step in ensuring AI tools meet high standards for safety and effectiveness. “Without this regulation, it could be like the wild west,” Shah noted.

For the past several years, the power and potential of AI in clinical practice has enthralled the industry. However, there is hesitation by organizations and clinicians about implementing AI deeply into clinical care – aka using AI to diagnose patients and identify diseases. One reason for that hesitation is that AI algorithms are a black box. Vendors do not make it clear how their algorithms are created, what data they were trained on, and any limitations they have run into while testing it.

Achieving FDA approval is an effective way to address this concern head-on.

“The FDA ask much more rigorous questions and have rigorous standards,” said Dr. Shah. “They know more about AI and how it works. They know about bias, drift and other concepts that were not thought about in the early days of AI.”

By investing the time and resources to meet the FDA’s stringent requirements, Qure.ai is able to show potential buyers that its AI tools are validated. This builds trust which is key to getting their technology adopted by radiologists and healthcare providers.

Qure.ai Continues to Expand AI Usage

Beyond the regulatory triumphs, Qure.ai’s is continuing to push forward to expand the use of its AI solutions. Building on their expertise with plain film, the company is using AI to “distinguish normal from abnormal chest x-rays and looking at fracture detection in fifteen different extremities” according to Dr. Shah.

The company is also working to helping to alleviate the administrative workload on radiologists.

“We are pushing forward with solutions that make a measurable difference,” Dr. Shah emphasized, pointing to their efforts in lung cancer detection as a prime example of the impactful they can have.

By seeking FDA clearance for its AI technology, Qure.ai is paving the way for a more trusted future for AI in healthcare.

Learn more about Qure.ai at https://www.qure.ai/

Listen and subscribe to the Healthcare IT Today Interviews Podcast to hear all the latest insights from experts in healthcare IT.

And for an exclusive look at our top stories, subscribe to our newsletter and YouTube.

Tell us what you think. Contact us here or on Twitter at @hcitoday. And if you’re interested in advertising with us, check out our various advertising packages and request our Media Kit.